| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.77 [0.63, 0.94] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.72 [0.60, 0.87] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.92 [0.77, 1.10] | | < 1 | | 0% | 1 study (1/-) | 82.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.97 [0.69, 1.37] | | > 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 1.00 [0.69, 1.46] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.21 [0.71, 2.07] | | < 1 | | 0% | 1 study (1/-) | 24.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.27 [0.89, 1.83] | | < 1 | | 0% | 1 study (1/-) | 9.4 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.71 [0.30, 1.72] | | < 1 | | 0% | 1 study (1/-) | 77.5 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.12 [0.78, 1.61] | | < 1 | | 0% | 1 study (1/-) | 26.6 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.45 [0.57, 3.65] | | < 1 | | 0% | 1 study (1/-) | 21.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.38 [0.89, 2.14] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.22 [0.40, 3.67] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 1.30 [0.92, 1.82] | | < 1 | | 0% | 1 study (1/-) | 6.8 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.04 [0.15, 7.44] | | < 1 | | 0% | 1 study (1/-) | 48.4 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.59 [0.64, 3.94] | | < 1 | | 0% | 1 study (1/-) | 16.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.62 [0.15, 2.62] | | < 1 | | 0% | 1 study (1/-) | 74.2 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.85 [0.87, 3.97] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 1.90 [1.15, 3.13] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.34 [0.07, 1.71] | | < 1 | | 0% | 1 study (1/-) | 90.4 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.51 [0.21, 1.20] | | < 1 | | 0% | 1 study (1/-) | 93.9 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 0.88 [0.55, 1.41] | | < 1 | | 0% | 1 study (1/-) | 70.4 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 2.03 [1.04, 3.97] | | < 1 | | 0% | 1 study (1/-) | 2.0 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.52 [0.02, 15.54] | | < 1 | | 0% | 1 study (1/-) | 64.5 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.97 [0.47, 2.01] | | < 1 | | 0% | 1 study (1/-) | 52.9 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.85 [0.56, 1.30] | | < 1 | | 0% | 1 study (1/-) | 77.1 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.08 [0.07, 62.36] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.63 [0.51, 13.67] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.06 [0.01, 0.44] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.10 [0.02, 0.45] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.11 [0.03, 0.35] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 2.40 [1.11, 5.16] | | < 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.04 [0.58, 1.89] | | < 1 | | 0% | 1 study (1/-) | 44.4 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.47 [0.46, 4.68] | | < 1 | | 0% | 1 study (1/-) | 25.9 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 2.09 [0.19, 23.16] | | < 1 | | 0% | 1 study (1/-) | 27.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.41 [0.08, 2.14] | | < 1 | | 0% | 1 study (1/-) | 85.4 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 2.63 [0.51, 13.67] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.65 [1.10, 2.49] | | < 1 | | 0% | 1 study (1/-) | 0.8 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.04 [0.41, 2.66] | | < 1 | | 0% | 1 study (1/-) | 46.6 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders AE (grade 3-4) | 1.39 [1.00, 1.94] | | < 1 | | 0% | 1 study (1/-) | 2.7 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.37 [0.59, 3.18] | | < 1 | | 0% | 1 study (1/-) | 23.2 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.04 [0.39, 2.81] | | < 1 | | 0% | 1 study (1/-) | 46.8 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.39 [0.31, 6.28] | | < 1 | | 0% | 1 study (1/-) | 33.4 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.52 [0.75, 3.08] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.61 [0.84, 3.11] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders AE (grade 3-4) | 1.43 [0.89, 2.29] | | < 1 | | 0% | 1 study (1/-) | 6.7 % | NA | not evaluable | | non important | - |
| General disorders and administration site conditions AE (grade 3-4) | 1.71 [1.09, 2.67] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 17.10 [0.98, 299.27] | | < 1 | | 0% | 1 study (1/-) | 2.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.41 [0.08, 2.14] | | < 1 | | 0% | 1 study (1/-) | 85.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.57 [0.25, 1.31] | | < 1 | | 0% | 1 study (1/-) | 90.6 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders AE (grade 3-4) | 1.11 [0.76, 1.63] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.97 [1.02, 3.78] | | < 1 | | 0% | 1 study (1/-) | 2.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.98 [0.48, 1.98] | | < 1 | | 0% | 1 study (1/-) | 52.5 % | NA | not evaluable | | non important | - |
| Nervous system disorders AE (grade 3-4) | 0.90 [0.48, 1.67] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.80 [0.53, 1.22] | | < 1 | | 0% | 1 study (1/-) | 85.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 0.77 [0.38, 1.53] | | < 1 | | 0% | 1 study (1/-) | 77.4 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.06 [0.01, 0.44] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders AE (grade 3-4) | 1.90 [0.63, 5.75] | | < 1 | | 0% | 1 study (1/-) | 12.8 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders AE (grade 3-4) | 2.56 [1.33, 4.91] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 2.10 [0.38, 11.53] | | < 1 | | 0% | 1 study (1/-) | 19.8 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders AE (grade 3-4) | 1.22 [0.40, 3.67] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 2.52 [1.18, 5.39] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.00 [0.56, 1.78] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Vascular disorders AE (grade 3-4) | 1.57 [0.80, 3.09] | | < 1 | | 0% | 1 study (1/-) | 9.6 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.31 [0.51, 3.37] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 2.83 [0.74, 10.76] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
